Imfinzi by AstraZeneca gets US approval for bladder cancer treatment

Investing.com -- AstraZeneca (NASDAQ:AZN)’s drug, Imfinzi, has received approval in the United States for the treatment of adult patients suffering from muscle-invasive bladder cancer, according to an official statement.

The approval allows the use of Imfinzi in combination with two other drugs, gemcitabine and cisplatin, as a neoadjuvant treatment. Following this, Imfinzi will be used as an adjuvant monotherapy after a surgical procedure known as radical cystectomy.

The treatment regimen involving Imfinzi has shown to reduce the risk of death by 25% compared to the use of neoadjuvant chemotherapy with radical cystectomy alone.

This development marks a significant step forward in the treatment options available for muscle-invasive bladder cancer patients.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.Should you invest $2,000 in AZN right now?

Before you buy stock in AZN, consider this: ProPicks AI are 6 easy-to-follow model portfolios created by Investing.com for building wealth by identifying winning stocks and letting them run. Over 150,000 paying members trust ProPicks to find new stocks to buy – driven by AI. The ProPicks AI algorithm has just identified the best stocks for investors to buy now. The stocks that made the cut could produce enormous returns in the coming years. Is AZN one of them?

Reveal Undervalued Stocks Now